Wegener's granulomatosis and pregnancy. ¿Perinatal risk?
Keywords:
necrotizing granulomatous vasculitis, glomeruli, neutrophil cytoplasmic antibodies, ANCA, Wagener's granulomatosis, perinatal riskAbstract
Wegener's granulomatosis is a necrotizing granulomatous vasculitis that affects the upper respiratory tract, lower and glomeruli. This and microscopic polyangiitis are vascular diseases associated with neutrophil cytoplasmic antibodies. Wegener's granulomatosis is a rare disease, cause not yet defined, with an incidence of 0.4 cases per 100,000 inhabitants. The literatura review updates the knowledge about this disease that allow the professionals to diagnose keep it in mind to try and it faces the perinatal risk.Downloads
References
Vera-Lastra OL, Halabe-Cherem J, Jara LJ. Vasculitis sistémicas. Conceptos generales. En: Vera-Lastra OL, Halabe-Cherem J, eds. Vasculitis. México DF: Ed. Alfil; 2006. p, 1-4
Goodman GC, Churg J. Wegener’s granulomatosis: pathology and review of the literature. Arch Pathol 1954; 58:533-53.
Osaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56:87-96.
García Arpa M, Porras Leal L, Romero Aguilera G, Vera Iglesias E, García Rojo M, Sánchez Caminero P, Cortina de la Calle P. Encías “en fresa” como manifestación inicial de enfermedad de Wegener. Med Cutan Iber Lat Am. 2009;37(5):217-20.
Philip Seo, MD, MHS. Embarazo y vasculitis. Rheum Dis Clin N Am 2007;33:99-317.
Wiik AS, Gordon TP, Kavanaugh AF. Cutting edge diagnostic in rheumatology: the rol of patients, clinicians and laboratory scientists in optimizing the use of autoinmune serology. Arthritis Rheum 2004;51:291-8
Keyla C, Ibañez S, Barba D. Granulomatosis de Wegener. Reporte de un caso. Rev méd cient. 2010;23(2):61-71.
Haris M, Koulaouzidis A, Yasir M, Clark S, Kaleem M, Mallya R, et al. Wegener´s Granulomatosis. CMAJ. 2008;178(1):25-6.
Vera-Lastra OL. Abordaje diagnóstico de las vasculitis. En: Vera-Lastra OL, Halabe Cherem J, eds. Vasculitis. México DF: Ed. Alfil; 2006. p. 77-99.
Flores-Suárez F. Granulomatosis de Wegener. En: Vera-Lastra O, Halabe-Cherem J, eds. Vasculitis. México DF: Ed. Alfil; 2006. p. 179-87
Granulomatosis de Wegener. En Manual A MIR de Reumatología. Colectivo de autores. [documento en Internet]. 2008[citado el 6 de julio de 2013];3ed. Madrid: Ed. Academia AMIR. p. 20-1. Disponible en:www.academiamir.com
Vera Lastra O, Olvera Acevedo A, McDonal Vera A, Pacheco Ruelas M, Gayosso Rivera JÁ. Granulomatosis de Wegener, abordaje diagnóstico y terapêutico. Gac Méd Méx 2009;146(2):121-9
Salazar, Kenneth. Granulomatosis de Wegener y vasculitis asociadas con anticuerpos anticitoplasma de neutrófilos (ANCA). Revista médica de Costa Rica y Centroamérica. 2008;583:175-7.
Schoe F. Vasos sanguíneos: granulomatodis dce Wegener. En Robins y Cotran. Patología estructural y funcional. 7ed. Kumar-Abbas-Fausto editors. Madrid: Ed. Doyma; 2007. p. 547
Pesci A, Manganelli P. Involvement of the respiratory system an ANCA associated systemic vasculitides: clinical and pathologic hallmarks and treatment. Drugs 2007; 8:25-42.Pagnoux C, Teixeira L. Wegener’s granulomatosis. Presse Med.2007;36(5Pt2):860-74.
Colectivo de Autores. HARRISON ONLINE 17 ed. > Parte XIII. [libro en Internet]. Trastornos del sistema inmunitario, el tejido conectivo y las articulaciones > Sección 2. Trastornos mediados por mecanismos inmunitarios > Capítulo 306. Síndromes de las vasculitis > Granulomatosis de Wegener [citado 5 julio 2013]. Disponible en:: http://www.harrisonmedicina.com/popup.aspx?aID=95157&print=yes
Patricia M Fortin, Aaron M Tejani, Ken Bassett, Vijaya M Musini. Inmunoglobulina intravenosa como tratamiento adyuvante para la granulomatosis de Wegener (Revision Cochrane traducida).[documento en Internet]. Biblioteca Cochrane Plus 2009 [citado 5 julio 2013]. Número 3. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com
Iglesias-Gamarra, Antonio; Coral, Paola, et al. Historia de las vasculitis primarias en Latinoamérica. Revista colombiana de Reumatología. 2007;14:261-86.
Leavitt RY, Fauci AS. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis.Arthritis Rheum.1990;8:1101-07
Jayne, David; Gaskin, Gill. Randomized trial of plasma exchange or high dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-88.
Hiemstra, Thomas, et al. Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. JAMA. 2010;304:2381-88.
Calzada Algrávez JL, Jaramillo Ramírez H, Delgadillo Márquez G, Macías Díaz DM. Granulomatosis de Wegener: presentación de un caso clínico y revisión de la bibliografía. Med Int Mex. 2012;28(5):504-7
Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. Journal of the American Society of Nephrology. 2004;15(3):717-21.
Chung SA, Seo P. Advances in the use of biologic agents for the treatment of systemic vasculitis. Current Opinion in Rheumatology. 2009;21:3-9.
De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis & Rheumatism. 2005;52(8):2461-9.
Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener's granulomatosis.. Current Opinion in Rheumatology. 2006;18(1):25-32.
Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. New England Journal of Medicine. 2003;349(1):36-44.
The Wegener's Granulomatosis Etanercept Trial (WGET) New England Journal of Medicine. 2005;352(4):351-61.
Wung PK, Stone JH. Therapeutics of Wegener's granulomatosis. Nature Clinical Practice Rheumatology. 2006;2(4):192-200.
Ara J. Tratamiento de las vasculitis ANCA positivas. nefr oPLUS. 2010;3(1):28-38
Roccatello D, Baldovino S, Alpa M, Rossi D, Napoli F, Naretto C. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol. 2008;26 Suppl 49:67-71.
Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180-8.
De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al.; EUVAS. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670-80.
Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant. 2008;23:1307-12.
Besáis N, Moulakakis KG, Lioupis C. Wegener’s granulomatosis presenting during pregnancy with acute limb ischemia. J Vasc Surg. 2005;42:800-4.
Luisiri P, Lance NJ, Curran JJ. Wegener’s granulomatosis in pregnancy. Arthritis Rheum. 199740:1354-60.
Auzary C, Huong DT, Wechsler B. Pregnancy in patients with Wegener’s granulomatosis: report of five cases. Ann Rheum Desease. 2000;59 800-4.
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
